Translating transplantation tolerance in the clinic: where are we, where do we go?
- PMID: 19250278
- PMCID: PMC2759462
- DOI: 10.1111/j.1365-2249.2009.03887.x
Translating transplantation tolerance in the clinic: where are we, where do we go?
Abstract
Research networks dedicated to translation of immune tolerance in the clinic currently support pilot trials aiming at immunosuppression withdrawal in kidney or liver allograft recipients. Although results obtained so far indicate that significant hurdles still need to be overcome before organ transplant recipients can be weaned off drugs safely and routinely, recent advances suggest that immunosuppression minimization on the basis of validated biomarkers might become standard practice in a near future.
References
-
- Billingham RE, Brent L, Medawar PB. Actively acquired tolerance’ of foreign cells. Nature. 1953;172:603–6. - PubMed
-
- Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14:417–24. - PubMed
-
- Dey B, Sykes M, Spitzer TR. Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine (Baltimore) 1998;77:355–69. - PubMed
-
- Hamawi K, De Magalhaes-Silverman M, Bertolatus JA. Outcomes of renal transplantation following bone marrow transplantation. Am J Transplant. 2003;3:301–5. - PubMed
-
- Monaco AP, Clark AW, Wood ML, Sahyoun AI, Codish SD, Brown RW. Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery. 1976;79:384–92. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources